Press Release

Mass Eye and Ear Malden location

Massachusetts Eye and Ear expands to Malden

March 6, 2017

Boston, Mass. — Massachusetts Eye and Ear opened a new ophthalmology (eye care) practice at 578 Main Street in Malden, Mass., on March 6. Mass. Eye and Ear, Malden is the hospital’s 19th location designed to bring the expertise of Mass. Eye and Ear specialists to the surrounding greater Boston area.

The Malden location offers comprehensive ophthalmology, including cataract surgery and contact lenses, as well as eye plastics services. The practice office also plans to Read more about Massachusetts Eye and Ear expands to Malden

Researchers identify factors responsible for chronic nature of autoimmune disease

Researchers identify factors responsible for chronic nature of autoimmune disease

January 4, 2017

Boston, Mass. — Researchers from Schepens Eye Research Institute of Massachusetts Eye and Ear have uncovered two factors responsible for the chronic, lifelong nature of autoimmune disorders, which tend to “flare up” intermittently in affected patients. These two factors are cell-signaling proteins called cytokines—specifically Interleukin-7 and -15 (IL-7 and IL-15)—that are secreted by cells of the immune system and help modulate memory Th17 cells, a subset of T cells which are known to contribute to autoimmune disorders. Until now, it was unclear how Th17 cells maintained Read more about Researchers identify factors responsible for chronic nature of autoimmune disease

Luk Vandenberghe

Luk H. Vandenberghe, PhD, receives RPB Nelson Trust Award for Retinitis Pigmentosa

December 21, 2016

Boston, Mass. — Luk H. Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and an Assistant Professor of Ophthalmology at Harvard Medical School, has been awarded a Nelson Trust Award for Retinitis Pigmentosa by Research to Prevent Blindness (RPB) in the amount of $100,000 over two years. The Nelson Trust Award was established to stimulate, strengthen and accelerate research to improve the diagnosis and treatment of retinitis pigmentosa. Dr. Read more about Luk H. Vandenberghe, PhD, receives RPB Nelson Trust Award for Retinitis Pigmentosa

New glasses may help minimize peripheral vision loss

New glasses may help minimize peripheral vision loss

December 19, 2016

Information for this release was provided by the Association for Research in Vision and Ophthalmology.

Rockville, Md. — Vision scientists may have discovered how to reduce pedestrian collisions in crowded and chaotic open space environments like bus terminals, shopping malls and city plazas involving individuals with partial blindness. Researchers have determined from which direction collisions with partially blind pedestrians are most likely to originate. This understanding will guide the development of new glasses that expand the sight of a person with Read more about New glasses may help minimize peripheral vision loss

Mass. Eye and Ear offering new treatment to stop progressive vision loss in patients with keratoconus

October 12, 2016

Ophthalmologists at Mass. Eye and Ear among the most experienced nationwide with newly FDA-approved corneal cross-linking procedure

Boston, Mass. — Ophthalmologists at Massachusetts Eye and Ear are currently accepting patients who may be candidates for a newly FDA-approved outpatient procedure known as “corneal cross-linking.” Corneal cross-linking is a stabilizing treatment to halt the progression of keratoconus, a degenerative eye condition in which the cornea becomes thin and Read more about Mass. Eye and Ear offering new treatment to stop progressive vision loss in patients with keratoconus

Researchers shed light on repair mechanism for severe corneal injuries

Researchers shed light on repair mechanism for severe corneal injuries

October 3, 2016

New findings may pave the way for the development of pharmaceutical therapies to reverse corneal scarring

Boston, Mass. —  In cases of severe ocular trauma involving the cornea, wound healing occurs following intervention, but at the cost of opaque scar tissue formation and damaged vision. Recent research has shown that mesenchymal stem cells (MSCs) — which can differentiate into a variety of cells, including bone, cartilage, muscle and fat cells — are capable of returning clarity to scarred corneas; however, the mechanisms by which this Read more about Researchers shed light on repair mechanism for severe corneal injuries

michael gilmore

Mass. Eye and Ear team discovers, successfully treats new variant of antibiotic-resistant bacterium

September 15, 2016

Boston, Mass. —  Researchers at Massachusetts Eye and Ear have discovered a new mutation in a highly antibiotic-resistant strain of E. coli that resists clearance by the body’s own immune system by inhibiting white blood cells that ordinarily kill and remove bacteria. In a paper published online today in JAMA Ophthalmology, the researchers describe the case that led them to discover the mutation, and offer suggestions for how to recognize and address this Read more about Mass. Eye and Ear team discovers, successfully treats new variant of antibiotic-resistant bacterium

Researchers find proliferating cells in normal and diseased corneal endothelium

Researchers find proliferating cells in normal and diseased corneal endothelium

September 14, 2016

Findings published in the American Journal of Pathology offer new directions for treatment of patients with Fuchs’ Endothelial Corneal Dystrophy (FECD)

Boston, Mass. —  Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as “neural crest-derived progenitor cells”) in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs’ Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea clear die Read more about Researchers find proliferating cells in normal and diseased corneal endothelium

Luk Vandenberghe

Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear

September 12, 2016
  • The strategic licensing agreement between Lonza and Massachusetts Eye and Ear® underscores Lonza’s position as a leading AAV manufacturing service provider and offers customers unprecedented technology and services to commercialize next generation gene therapies.
  • The Anc-AAV vector platform has the potential to overcome pre-existing immunity in order to treat more patients compared with other viral vectors currently in development.
  • Anc80, the lead novel Anc-AAV available for sublicensing, is a potent gene therapy vector capable of superior gene expression levels in Read more about Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear